Replies to post #322145 on Avid Bioservices Inc (CDMO)

[biopharm]

Roger Lias and the entire BODs should receive that info, with those companies listed with PS Targeting mentioned in their patents and/or related to Biomarkers due to PS Targeting and shareholders are left in the dark about all those collaborations so all shareholders must shed light on this now via certified letters, now overnight express!

Patents that pertain to PS Targeting already been researched with other Big Pharma and this is why non-disclosed collaborations are important NOW, because Biomarkers are fast proving what works and what protein pathways / targets to go after, especially after collaborating with PS Targeting tech rights owned by Peregrine or Avid Bioservices as we are called now

Fiduciary Duties of these assets, IP assets.....are covered in Fiduciary Duties and are vital to make sure the current BODs are aware we are watching closely.

The law covering corporate director duties pertaining to management of intellectual property assets is evolving, making it important for directors to remain up-to- date on any and all changes in management procedures and best practices. Generally, courts treat intellectual property assets like any other corporate asset, which means directors must approach intellectual property with the same due care as they would any other asset.
For example, directors must be informed of the value of their intellectual property and always remember their duty of loyalty to their shareholders. Similarly, courts require directors to implement necessary internal controls to protect their corporation’s intellectual property assets. Finally, directors must refrain from misappropriating intellectual property. https://scholarlycommons.law.northwestern.edu/cgi/viewcontent.cgi?referer=&httpsredir=1&article=1254&context=njtip

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137507269